Information Provided By: 
Fly News Breaks for May 4, 2018
PCRX
May 4, 2018 | 07:38 EDT
JMP Securities analyst Donald Ellis noted that Pacira Pharmaceuticals reported Q1 earnings that were in-line with consensus and the company reiterated FY18 Exparel sales guidance. He lowered his price target on Pacira to $56 from $65 to account for his updated peer PEG ratios. Ellis maintains an Outperform rating on Pacira, stating that he believes the combination of the DPS partnership, scrutiny against opioids and recent approvals are contributing to the acceleration in Exparel sales.
News For PCRX From the Last 2 Days
There are no results for your query PCRX
